$1.94 Billion is the total value of PURA VIDA INVESTMENTS, LLC's 194 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| UNITEDHEALTH GROUP INCput | $31,810,800 | +5.0% | 60,000 | 0.0% | 1.64% | -6.3% | ||
| VANECK ETF TRUSTput | $31,096,000 | +15.6% | 400,000 | 0.0% | 1.60% | +3.1% | ||
| SAREPTA THERAPEUTICS INCcall | $25,916,000 | +17.2% | 200,000 | 0.0% | 1.34% | +4.5% | ||
| CYTK | CYTOKINETICS INC | $11,229,835 | -5.1% | 25,000 | 0.0% | 0.58% | -15.3% | |
| APELLIS PHARMACEUTICALS INCcall | $10,342,000 | -24.3% | 200,000 | 0.0% | 0.53% | -32.4% | ||
| CELLDEX THERAPEUTICS INC NEWcall | $8,762,462 | +58.6% | 196,600 | 0.0% | 0.45% | +41.2% | ||
| STAA | STAAR SURGICAL CO | $8,412,467 | -31.2% | 173,310 | 0.0% | 0.43% | -38.6% | |
| SPDR SER TRcall | $8,233,600 | +4.6% | 99,200 | 0.0% | 0.42% | -6.6% | ||
| TELA | TELA BIO INC | $5,980,909 | +35.0% | 520,079 | 0.0% | 0.31% | +20.7% | |
| OCX | ONCOCYTE CORP | $5,794,258 | -56.0% | 18,056,274 | 0.0% | 0.30% | -60.8% | |
| PFIZER INCcall | $5,124,000 | +17.1% | 100,000 | 0.0% | 0.26% | +4.3% | ||
| SDGR | SCHRODINGER INC | $4,859,400 | -25.2% | 260,000 | 0.0% | 0.25% | -33.2% | |
| TRUPANION INCput | $3,564,750 | -20.0% | 75,000 | 0.0% | 0.18% | -28.7% | ||
| SAREPTA THERAPEUTICS INCdebt 1.250% 9/1 | $2,893,750 | +11.9% | 25,000 | 0.0% | 0.15% | -0.7% | ||
| ORAMED PHARMACEUTICALS INCcall | $2,231,565 | +85.7% | 185,500 | 0.0% | 0.12% | +64.3% | ||
| GHRS | GH RESEARCH PLCordinary shares | $1,538,938 | -16.4% | 158,327 | 0.0% | 0.08% | -25.5% | |
| GERON CORPput | $1,508,386 | +3.4% | 623,300 | 0.0% | 0.08% | -7.1% | ||
| HZNP | HORIZON THERAPEUTICS PUB L | $1,468,020 | +84.0% | 12,900 | 0.0% | 0.08% | +65.2% | |
| PROMETHEUS BIOSCIENCES INCput | $1,375,000 | +86.3% | 12,500 | 0.0% | 0.07% | +65.1% | ||
| ALKS | ALKERMES PLC | $1,306,500 | +17.0% | 50,000 | 0.0% | 0.07% | +3.1% | |
| EXEL | EXELIXIS INC | $1,203,000 | +2.3% | 75,000 | 0.0% | 0.06% | -8.8% | |
| QGEN | QIAGEN NV | $548,570 | +20.8% | 11,000 | 0.0% | 0.03% | +7.7% | |
| TRAVERE THERAPEUTICS INCnote 2.250% 3/0 | $457,500 | -10.5% | 5,000 | 0.0% | 0.02% | -20.0% | ||
| VSTM | VERASTEM INC | $404,219 | -52.7% | 1,004,272 | 0.0% | 0.02% | -57.1% | |
| ROIVANT SCIENCES LTD*w exp 09/30/202 | $387,317 | +396.6% | 199,648 | 0.0% | 0.02% | +300.0% | ||
| NGM BIOPHARMACEUTICALS INCcall | $302,706 | -61.6% | 60,300 | 0.0% | 0.02% | -65.2% | ||
| GOSSAMER BIO INCnote 5.000% 6/0 | $161,750 | -68.7% | 5,000 | 0.0% | 0.01% | -73.3% | ||
| SVRA | SAVARA INC | $147,272 | +0.2% | 95,014 | 0.0% | 0.01% | -11.1% | |
| SOMALOGIC INC*w exp 08/31/202 | $81,760 | -9.2% | 204,401 | 0.0% | 0.00% | -20.0% | ||
| TALKW | TALKSPACE INC*w exp 06/21/202 | $31,142 | -72.4% | 427,194 | 0.0% | 0.00% | -71.4% | |
| SPRINGBIG HOLDINGS INC*w exp 06/14/202 | $211 | -78.9% | 10,000 | 0.0% | 0.00% | – | ||
| MAPSW | WM TECHNOLOGY INC*w exp 06/16/202 | $5,000 | -70.6% | 50,000 | 0.0% | 0.00% | -100.0% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ICU MED INC | 26 | Q2 2023 | 4.2% |
| NANOSTRING TECHNOLOGIES INC | 26 | Q2 2023 | 3.3% |
| VIEWRAY INC | 25 | Q2 2023 | 3.2% |
| LIVANOVA PLC | 23 | Q3 2023 | 3.8% |
| ALEXION PHARMACEUTICALS INC | 23 | Q1 2021 | 4.3% |
| INSPIRE MED SYS INC | 22 | Q3 2023 | 3.7% |
| BOSTON SCIENTIFIC CORP | 22 | Q3 2022 | 4.8% |
| INVACARE CORP | 22 | Q3 2021 | 2.8% |
| ESTABLISHMENT LABS HLDGS INC | 21 | Q3 2023 | 5.0% |
| INTERSECT ENT INC | 21 | Q2 2021 | 2.6% |
View PURA VIDA INVESTMENTS, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Stryve Foods Holdings, LLC | April 19, 2023 | 1,470,649 | 5.6% |
| ICAD INC | March 15, 2023 | 1,277,214 | 5.0% |
| ESTABLISHMENT LABS HOLDINGS INC. | February 14, 2023 | 1,002,767 | 4.1% |
| Pulmonx Corp | February 14, 2023 | 1,216,258 | 3.2% |
| Quotient LtdSold out | February 14, 2023 | 0 | 0.0% |
| Universe Pharmaceuticals INCSold out | February 14, 2023 | 0 | 0.0% |
| MedMen Enterprises, Inc. | April 29, 2022 | 139,755,072 | 21.4% |
| INVACARE CORPSold out | February 14, 2022 | 0 | 0.0% |
| MedAvail Holdings, Inc. | February 14, 2022 | 714,120 | 2.2% |
| TELA Bio, Inc. | February 14, 2022 | 564,120 | 3.9% |
View PURA VIDA INVESTMENTS, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2024-02-13 |
| SC 13D/A | 2023-12-29 |
View PURA VIDA INVESTMENTS, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.